Major beauty companies are testing skin treatments aimed at people worried about facial sagging and volume loss linked to rapid weight loss associated with obesity drugs. Galderma, Natura and L’Oréal are exploring products and clinical approaches for consumers who increasingly see changes in skin firmness and facial contours as a new beauty concern.
Outlets present the development as a market opportunity created by the wider obesity-drug boom, with the reported focus on the look often dubbed “Ozempic face.” Across the coverage, the emphasis is on companies designing or trialling treatments for skin laxity and reduced facial volume rather than on the underlying obesity drugs themselves. Retail Gazette frames the story as a “beauty boom” sparked by weight-loss jabs, while BNN Bloomberg and Business of Fashion highlight the new commercial category and the branding of the issue as “Ozempic face.”
